Literature DB >> 8359651

Flow cytometry and Zollinger-Ellison syndrome: relationship to clinical course.

D C Metz1, M Kuchnio, D L Fraker, D J Venzon, G Jaffe, R T Jensen, M Stetler-Stevenson.   

Abstract

BACKGROUND: With successful means of controlling gastric acid secretion in patients with Zollinger-Ellison syndrome, the gastrinoma itself is becoming the major determinant of long-term survival. No methods have yet been described to predict which tumors will have more malignant courses thereby indicating which patients should undergo aggressive surgery or antitumor therapy. Because DNA analysis, using flow cytometry, has proved helpful in this regard in other tumors, the current study was designed to evaluate its utility in gastrinoma patients.
METHODS: Flow cytometry was performed on 81 paraffin-embedded gastrinoma specimens from 59 patients. Results were compared with preoperative patient characteristics, findings at surgery, and postoperative follow up.
RESULTS: Tumors were diploid in 54% of patients, near diploid in 15%, pure tetraploid in 0%, nontetraploid aneuploid in 25%, and multiple stem line aneuploid in 5%. All patients with multiple stem line aneuploid tumors had wide-spread metastases whereas all patients with nontetraploid aneuploid tumors had localized or regional disease. Median S phase percentage was 3.6. S phase percentages were higher in patients with widespread metastatic disease than in patients with localized or regional disease. Disease extent also correlated closely with fasting serum gastrin level. After removing this variable with logistic regression analysis, the significant correlation between disease extent and DNA analysis persisted.
CONCLUSIONS: DNA analysis of gastrinoma tissue specimens correlates independently with the extent of disease and may be useful in planning therapeutic strategies for patients with Zollinger-Ellison syndrome.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8359651     DOI: 10.1016/0016-5085(93)90898-m

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  8 in total

Review 1.  Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.

Authors:  Robert T Jensen; Marc J Berna; David B Bingham; Jeffrey A Norton
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

2.  Prognostic factors in patients with endocrine tumours of the duodenopancreatic area.

Authors:  I Madeira; B Terris; M Voss; A Denys; A Sauvanet; J F Flejou; V Vilgrain; J Belghiti; P Bernades; P Ruszniewski
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

Review 3.  Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome.

Authors:  Fathia Gibril; Robert T Jensen
Journal:  Curr Gastroenterol Rep       Date:  2005-05

4.  Increased expression of CD44v6 in endocrine pancreatic tumours but not in midgut carcinoid tumours.

Authors:  B Terris; J F Fléjou; S Dubois; P Ruszniewski; J Y Scoazec; J Belghiti; F Potet; P Bernades; M Mignon; D Hénin
Journal:  Clin Mol Pathol       Date:  1996-08

Review 5.  Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome.

Authors:  Jeffrey A Norton; Robert T Jensen
Journal:  Ann Surg       Date:  2004-11       Impact factor: 12.969

6.  Forty-year appraisal of gastrinoma. Back to the future.

Authors:  E C Ellison
Journal:  Ann Surg       Date:  1995-10       Impact factor: 12.969

Review 7.  Is gastrinoma a medical disease?

Authors:  M Mignon; G Cadiot; J P Marmuse; M J Lewin
Journal:  Yale J Biol Med       Date:  1996 May-Jun

Review 8.  Zollinger-Ellison syndrome: past, present and future controversies.

Authors:  R T Jensen
Journal:  Yale J Biol Med       Date:  1994 May-Aug
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.